Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome
NCT04327934 · Yale University · EARLY_PHASE1 · terminated · last registry update 2024-02-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Unble to complete all arms of the planned study due to Covid stoppage and difficulty with recruiting and getting enrolled participants to return post Covid.” | – | Registry record, Yale University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GNRHR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-27Phase 3 first posted: Foresee Pharmaceuticals Co., Ltd., FP-014 (NCT06795178)
- 2025-01-27Phase 3 first posted: Foresee Pharmaceuticals Co., Ltd., Triptorelin Mesylate (NCT06795191)
- 2025-01-23Results posted on the registry: Astellas Pharma Inc, Enzalutamide + Androgen deprivation therapy (ADT) (NCT03641560)
- 2024-11-19Results posted on the registry: Janssen Research & Development, LLC, Apalutamide + ADT (NCT04523207)
- 2024-11-04Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., Relugolix + Relugolix placebo (NCT06671548)
- 2024-10-21Phase 3 first posted: Emory University, Abiraterone Acetate + Bicalutamide (NCT06650579)
- 2024-10-16Results posted on the registry: RTOG Foundation, Inc., Enzalutamide + Bicalutamide (NCT03809000)
- 2024-07-31Results posted on the registry: Pfizer, PF-06873600 + Endocrine Therapy 1 (NCT03519178)
- 2024-07-22Phase 3 first posted: Children's Oncology Group, Triptorelin Pamoate (NCT06513962)
- 2024-07-08Phase 3 first posted: Dongkook Pharmaceutical Co., Ltd., DKF-MA102 (NCT06490328)
- 2024-06-07Phase 3 first posted: Fudan University, Apatinib + CDK4/6 Inhibitor (NCT06447623)
- 2024-06-07Phase 3 first posted: Changchun GeneScience Pharmaceutical Co., Ltd., T Leuprolide Injectable Emulsion + Leuprorelin Acetate Microspheres for Injection (NCT06449027)
- 2024-06-03Phase 3 first posted: Main Line Health, 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate (NCT06439524)
- 2024-05-28Results posted on the registry: Ipsen, Triptorelin Pamoate (NCT05029622)
- 2024-05-14Results posted on the registry: National Cancer Institute (NCI), ADT (NCT03388619)
- 2024-04-30Phase 3 first posted: Xiaojun Chen, GnRH antagonist + Letrozole 2.5mg (NCT06390904)
- 2024-04-24Phase 3 first posted: MedSIR, Everolimus + Elacestrant (NCT06382948)
- 2024-04-23Phase 3 first posted: Xiaojun Chen, GnRH antagonist + Letrozole 2.5mg (NCT06379113)
- 2024-04-19Phase 3 first posted: Yale University, Elagolix 200 MG (NCT06375811)
- 2024-04-05Results posted on the registry: Novartis Pharmaceuticals, Ribociclib + Anastrozole (NCT03822468)
- 2024-03-27Results posted on the registry: Novartis Pharmaceuticals, Alpelisib + Fulvestrant (NCT03056755)
- 2024-03-25Results posted on the registry: Pfizer, Enzalutamide + Placebo (No longer applicable in Open Label study period) (NCT02319837)
- 2024-02-28Phase 3 first posted: Cancer Research Antwerp, Darolutamide + Darolutamide matched placebo (NCT06282588)
- 2024-01-08Phase 3 first posted: Institut Curie, Endocrine therapy + Endocrine therapy combined with the local treatment of FES-negative lesions (NCT06195709)
- 2023-12-20Results posted on the registry: SWOG Cancer Research Network, anastrozole + everolimus (NCT01674140)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision